Cargando…
Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma
The lack of information concerning individual variation in drug-metabolizing enzymes is one of the most important obstacles for designing personalized medicine approaches for hepatocellular carcinoma (HCC) patients. To assess cytochrome P450 (CYP) in the metabolism of endogenous and exogenous molecu...
Autores principales: | Zhou, Jun, Wen, Qiang, Li, Sai-Fei, Zhang, Yun-Fei, Gao, Na, Tian, Xin, Fang, Yan, Gao, Jie, Cui, Ming-Zhu, He, Xiao-Pei, Jia, Lin-Jing, Jin, Han, Qiao, Hai-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226607/ https://www.ncbi.nlm.nih.gov/pubmed/27203676 http://dx.doi.org/10.18632/oncotarget.9437 |
Ejemplares similares
-
Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach
por: Gao, Jie, et al.
Publicado: (2016) -
Correlation of Cytochrome P450 Oxidoreductase Expression with the
Expression of 10 Isoforms of Cytochrome P450 in Human Liver
por: Zhang, Hai-Feng, et al.
Publicado: (2016) -
Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs
por: Gao, Jie, et al.
Publicado: (2017) -
Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility
por: Li, Meng, et al.
Publicado: (2019) -
Identification of Cytochrome P450 2E1 as a Novel Target in Glioma and Development of Its Inhibitor as an Anti‐Tumor Agent
por: Hu, Guiming, et al.
Publicado: (2023)